Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge acts for EQT and the subsidiary company ESML Intressenter in connection with the takeover bid for Securitas Direct
Mandate

Vinge acts for EQT and the subsidiary company ESML Intressenter in connection with the takeover bid for Securitas Direct

November 13, 2007

Vinge is acting for EQT and the subsidiary company, jointly owned by EQT, SäkI AB, Melker Schörling AB and Investment AB Latour, in connection with the public cash offer to the shareholders of Securitas Direct AB. The offer also includes an offer to the holders of subscription options in Securitas Direct AB. Securitas Direct AB is listed on the OMX Nordic Stock Exchange. Vinge assists with stock exchange and corporate advice, financing, and acquisition structuring. The total value of the offer is appr. 9.6 billion kronor.

The Vinge team includes Hans Wibom, Michael Wigge, Ola Sandersson, Christoffer Saidac, Tuula Tallavaara, Dain Nevonen and Martin Hall. Fabian Ekeblad and Louise Salomon assist with the financing and Johan Karlsson and Peter Forsberg assist with the competition filing.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026